Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

2 Pros, 2 Cons for Buying Energy Transfer Right Now

By Josh Enomoto, InvestorPlace Contributor

With the markets starving for yield, a passive-income monster like ET stock may offer relief. However, do note the pros and cons before diving in.

Don’t Make a Blind Investment In Ocugen Stock

By Josh Enomoto, InvestorPlace Contributor

After Ocugen recently disappointed in a late-stage trial for one of its therapies, OCGN stock jumped higher. Is this a legitimate rally or merely a dead cat bounce?

Don’t Cancel Your Visit With Co-Diagnostics Stock Just Yet

By Josh Enomoto, InvestorPlace Contributor

CODX stock took a hit as economic indicators suggested a sooner-than-expected recovery. But don’t completely ignore shares just yet.

Why Inovio Pharmaceuticals May Get a Pass on Coronavirus Vaccine Hype

By Josh Enomoto, InvestorPlace Contributor

INO stock has its fair share of critics and under normal circumstances, those criticisms could cripple it. However, these are not normal circumstances.

Don’t Buy Royal Caribbean Cruises’ False Narrative

By Josh Enomoto, InvestorPlace Contributor

RCL stock along with the cruise ship industry has enjoyed remarkable bullishness recently. Unfortunately, the economic backdrop suggests this optimism is unjustified.

Load More